Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN).

< BACK TO ARCHIVE


Papers: 10 Aug 2019 - 16 Aug 2019


Human Studies, Pharmacology/Drug Development

PAIN TYPE:
Migraine/Headache


2019 Aug 13


BMC Neurol


http://www.ncbi.nlm.nih.gov/pubmed/31409292?dopt=Abstract


19


1

Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN).

Authors

Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN).
Loo L S, Plato BM, Turner IM, Case MG, Raskin J, Dowsett SA, Krege JH
BMC Neurol. 2019 Aug 13; 19(1):191.
PMID: 31409292.

Abstract

We studied the efficacy and safety of a second dose of lasmiditan for acute treatment of migraine.
Read This Paper